Key facts
- This page summarizes Harris Rotman's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Feb 2024, 17:03.
Harris Rotman - 01 Feb 2024 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)
- Reporting relationship
- SVP Regulatory Affairs
- Issuer ticker
- CNTA
- Reported as of
- 01 Feb 2024
- Net transaction value
- -$68,219
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2024, 17:03:52 UTC
- Prior SEC filing
- 22 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gregory Weinhoff, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Harris Rotman filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 02 Feb 2024.
Change
- Previous filing in this sequence was filed on 22 Sep 2023.
- Current net transaction value: -$68,219.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNTA
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +37,500
- Change %
- +112%
- Price
- $0.000000
- Shares after
- 71,000
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
CNTA
transaction
Ordinary Shares
Tax liability
- Transaction value
- $33,645
- Shares
- -4,108
- Change %
- -5.8%
- Price
- $8.19
- Shares after
- 66,892
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F3
CNTA
transaction
Ordinary Shares
Sale
- Transaction value
- $34,574
- Shares
- -4,267
- Change %
- -6.4%
- Price
- $8.10
- Shares after
- 62,625
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNTA
transaction
Derivative
Share Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 01 Feb 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 75,000
- Exercise price
- $8.01
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 6 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2025.
Footnote F3
Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
Footnote F4
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 20, 2023.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.83 to $8.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F6
1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.